Coloplast A/S (COLO B.CO) Stock Price

Coloplast A/S Price

OMX·CLOSED
429.40DKK-4.70 (-1.09 %)
Market closed

Revenue has compounded at 7.2% per year over the past 10 years to 27.87 B DKK. Earnings per share have grown at 14.3% per year over the last 10 years. Coloplast A/S's net margin stands at 13.0%, down from 24.8% several years earlier. Coloplast A/S currently offers a dividend yield of about 5.36%. The payout ratio is around 143% of earnings. The dividend has grown at 6.3% per year over the past 10 years. Analysts set a median price target of 642.60 DKK, implying 49.7% above the current price. Of 27 analysts, 9 rate the stock a buy — an overall Hold consensus. The stock trades about 16% above its 52-week low.

Coloplast A/S stock price

Volume
Ex-Dividend
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Coloplast A/S over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Coloplast A/S stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Coloplast A/S's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Coloplast A/S Stock Price History
DateColoplast A/S Price
7/31/2026429.40 DKK
7/30/2026434.10 DKK
7/29/2026435.40 DKK
7/28/2026430.70 DKK
7/27/2026420.10 DKK
7/24/2026403.60 DKK
7/23/2026399.50 DKK
7/22/2026411.80 DKK
7/21/2026414.10 DKK
7/20/2026418.40 DKK
7/17/2026425.70 DKK
7/16/2026414.00 DKK
7/15/2026408.60 DKK
7/14/2026396.50 DKK
7/13/2026401.20 DKK
7/10/2026401.00 DKK
7/9/2026400.50 DKK
7/8/2026398.60 DKK
7/7/2026406.50 DKK
7/6/2026397.60 DKK
7/3/2026394.70 DKK
7/2/2026396.60 DKK
7/1/2026378.70 DKK
6/30/2026372.30 DKK
6/29/2026377.60 DKK
6/26/2026381.90 DKK
6/25/2026382.40 DKK
6/24/2026379.00 DKK
6/23/2026375.70 DKK
6/22/2026374.70 DKK
6/19/2026382.00 DKK
6/18/2026371.60 DKK
6/17/2026376.80 DKK
6/16/2026379.40 DKK
6/15/2026386.40 DKK
6/12/2026379.70 DKK
6/11/2026381.20 DKK
6/10/2026382.80 DKK
6/9/2026386.70 DKK
6/8/2026383.70 DKK
6/4/2026383.70 DKK
6/3/2026379.10 DKK
6/2/2026378.00 DKK
6/1/2026382.00 DKK
5/29/2026395.80 DKK
5/28/2026397.70 DKK
5/27/2026404.90 DKK
5/26/2026404.00 DKK
5/22/2026403.60 DKK
5/21/2026413.80 DKK
5/20/2026411.90 DKK
5/19/2026404.40 DKK
5/18/2026404.30 DKK
5/13/2026399.30 DKK
5/12/2026407.10 DKK
5/11/2026400.50 DKK
5/8/2026402.60 DKK
5/7/2026410.80 DKK
5/6/2026410.40 DKK
5/5/2026404.50 DKK
5/4/2026407.70 DKK
5/1/2026402.80 DKK
4/30/2026393.90 DKK
4/29/2026398.10 DKK
4/28/2026408.20 DKK
4/27/2026403.90 DKK
4/24/2026413.10 DKK
4/23/2026420.30 DKK
4/22/2026423.40 DKK
4/21/2026428.20 DKK
4/20/2026435.90 DKK
4/17/2026448.50 DKK
4/16/2026433.40 DKK
4/15/2026433.70 DKK
4/14/2026429.80 DKK
4/13/2026424.90 DKK
4/10/2026428.50 DKK
4/9/2026421.10 DKK
4/8/2026434.90 DKK
4/7/2026432.75 DKK
4/1/2026442.51 DKK
3/27/2026431.92 DKK
3/26/2026435.03 DKK
3/25/2026432.92 DKK
3/24/2026426.23 DKK
3/23/2026425.18 DKK
3/20/2026424.53 DKK
3/19/2026425.77 DKK
3/18/2026446.10 DKK
3/17/2026456.90 DKK
3/16/2026453.40 DKK
3/13/2026447.40 DKK
3/12/2026439.80 DKK
3/11/2026441.50 DKK
3/10/2026453.60 DKK
3/9/2026448.80 DKK
3/6/2026461.50 DKK
3/5/2026461.70 DKK
3/4/2026464.00 DKK
3/3/2026466.70 DKK
3/2/2026482.80 DKK
2/27/2026488.00 DKK
2/26/2026481.20 DKK
2/25/2026482.00 DKK
2/24/2026488.80 DKK
2/23/2026481.40 DKK
2/20/2026483.00 DKK
2/19/2026479.70 DKK
2/18/2026484.50 DKK
2/17/2026484.70 DKK
2/16/2026475.10 DKK
2/13/2026488.60 DKK
2/12/2026492.10 DKK
2/11/2026489.00 DKK
2/10/2026491.90 DKK
2/9/2026481.00 DKK
2/6/2026493.50 DKK
2/5/2026537.40 DKK
2/4/2026540.20 DKK
2/3/2026523.00 DKK
2/2/2026536.60 DKK
1/30/2026536.00 DKK
1/29/2026541.40 DKK
1/28/2026533.40 DKK
1/27/2026538.00 DKK
1/26/2026540.00 DKK
1/23/2026541.80 DKK
1/22/2026553.00 DKK
1/21/2026547.40 DKK
1/20/2026538.80 DKK
1/19/2026542.80 DKK
1/16/2026577.40 DKK
1/15/2026576.80 DKK
1/14/2026572.80 DKK
1/13/2026576.40 DKK
1/12/2026573.80 DKK
1/9/2026566.00 DKK
1/8/2026563.80 DKK
1/7/2026563.00 DKK
1/6/2026562.00 DKK
1/5/2026542.20 DKK
1/2/2026536.40 DKK
12/30/2025546.40 DKK
12/29/2025544.00 DKK
12/23/2025542.80 DKK
12/22/2025547.80 DKK
12/19/2025548.00 DKK
12/18/2025543.40 DKK
12/17/2025549.00 DKK
12/16/2025551.60 DKK
12/15/2025560.80 DKK
12/12/2025564.00 DKK
12/11/2025564.20 DKK
12/10/2025562.60 DKK
12/9/2025564.60 DKK
12/8/2025561.80 DKK
12/5/2025581.20 DKK
12/4/2025585.20 DKK
12/3/2025578.60 DKK
12/2/2025577.40 DKK
12/1/2025589.20 DKK
11/28/2025580.80 DKK
11/27/2025584.20 DKK
11/26/2025583.00 DKK
11/25/2025587.20 DKK
11/24/2025579.00 DKK
11/21/2025580.20 DKK
11/20/2025577.00 DKK
11/19/2025570.60 DKK
11/18/2025577.40 DKK
11/17/2025574.00 DKK
11/14/2025589.00 DKK
11/13/2025601.80 DKK
11/12/2025605.80 DKK
11/11/2025602.20 DKK
11/10/2025600.20 DKK
11/7/2025603.00 DKK
11/6/2025613.40 DKK
11/5/2025614.80 DKK
11/4/2025610.40 DKK
11/3/2025582.60 DKK
10/31/2025585.60 DKK
10/30/2025589.40 DKK
10/29/2025593.60 DKK
10/28/2025599.20 DKK
10/27/2025602.40 DKK
10/24/2025609.20 DKK
10/23/2025605.60 DKK
10/22/2025602.40 DKK
10/21/2025595.60 DKK
10/20/2025592.20 DKK
10/17/2025585.60 DKK
10/16/2025584.60 DKK
10/15/2025572.40 DKK
10/14/2025564.40 DKK
10/13/2025570.00 DKK
10/10/2025565.60 DKK
10/9/2025576.40 DKK
10/8/2025580.60 DKK
10/7/2025575.00 DKK
10/6/2025575.00 DKK
10/3/2025570.60 DKK
10/2/2025573.60 DKK
10/1/2025557.60 DKK
9/30/2025543.00 DKK
9/29/2025551.40 DKK
9/26/2025550.60 DKK
9/25/2025550.40 DKK
9/24/2025571.40 DKK
9/23/2025580.00 DKK
9/22/2025581.00 DKK
9/19/2025592.40 DKK
9/18/2025594.60 DKK
9/17/2025587.60 DKK
9/16/2025596.60 DKK
9/15/2025610.00 DKK
9/12/2025616.40 DKK
9/11/2025615.20 DKK
9/10/2025630.40 DKK
9/9/2025625.20 DKK
9/8/2025621.80 DKK
9/5/2025628.60 DKK
9/4/2025617.00 DKK
9/3/2025620.00 DKK
9/2/2025609.60 DKK
9/1/2025623.80 DKK
8/29/2025612.80 DKK
8/28/2025608.60 DKK
8/27/2025610.20 DKK
8/26/2025610.40 DKK
8/25/2025615.00 DKK
8/22/2025616.00 DKK
8/21/2025619.40 DKK
8/20/2025630.60 DKK
8/19/2025604.40 DKK
8/18/2025612.00 DKK
8/15/2025603.60 DKK
8/14/2025599.00 DKK
8/13/2025602.20 DKK
8/12/2025605.40 DKK
8/11/2025603.80 DKK
8/8/2025601.40 DKK
8/7/2025606.40 DKK
8/6/2025589.80 DKK
8/5/2025601.80 DKK
8/4/2025598.40 DKK
Access this data via the Eulerpool API
Get Free API Key

Coloplast A/S Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
24.50 B DKK
6.85 B DKK
4.78 B DKK
Jan 1, 2024
27.03 B DKK
7.29 B DKK
5.05 B DKK
Jan 1, 2025
27.87 B DKK
7.67 B DKK
3.64 B DKK
Jan 1, 2026 (e)
29.37 B DKK
8.18 B DKK
5.88 B DKK
Jan 1, 2027 (e)
31.47 B DKK
8.97 B DKK
6.48 B DKK
Jan 1, 2028 (e)
33.51 B DKK
9.77 B DKK
7.11 B DKK
Jan 1, 2029 (e)
35.92 B DKK
10.08 B DKK
7.60 B DKK
Jan 1, 2030 (e)
38.53 B DKK
10.94 B DKK
8.27 B DKK

Coloplast A/S Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 3, 2026, 10:30 AM
 
REVENUEB DKK
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEB DKK
EBITB DKK
EBIT MARGIN%
NET INCOMEB DKK
NET INCOME GROWTH%
DIV.DKK
DIV. GROWTH%
SHARESM
20162017201820192020202120222023202420252026e2027e2028e2029e2030e2031e
14.6815.5316.4517.9418.5419.4322.5824.5027.0327.8729.3731.4733.5135.9238.5340.73
5.555.775.939.063.374.7616.238.5110.333.125.387.136.507.187.285.71
68.3368.0867.2767.7568.0168.5368.7866.6467.5967.9767.9767.9767.9767.9767.9767.97
10.0310.5711.0712.1512.6113.3115.5316.3318.2718.9519.9621.3922.7824.4126.1927.69
4.855.025.095.565.856.366.916.857.297.678.188.979.7710.0810.94–
33.0132.3530.9530.9731.5732.7130.6027.9426.9627.5227.8628.4929.1528.0728.39–
3.143.803.853.874.204.834.714.785.053.645.886.487.117.608.27–
249.6120.811.260.738.3714.96-2.471.645.62-28.0361.7210.179.806.828.82–
13.5015.0016.0017.0018.0019.0020.0021.0022.7123.0036.0038.1540.42–––
8.0011.116.676.255.885.565.265.008.141.2856.525.975.95–––
212.50212.50212.40213.10213.30213.20212.80215.50224.90225.40225.40225.40225.40225.40225.40225.40
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Coloplast A/S generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Coloplast A/S retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Coloplast A/S's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Coloplast A/S has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Coloplast A/S's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Coloplast A/S stock margins

The Coloplast A/S margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Coloplast A/S. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Coloplast A/S.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
68.53 %
32.71 %
24.84 %
Jan 1, 2022
68.78 %
30.60 %
20.84 %
Jan 1, 2023
66.64 %
27.94 %
19.52 %
Jan 1, 2024
67.59 %
26.96 %
18.69 %
Jan 1, 2025
67.97 %
27.52 %
13.04 %
Jan 1, 2026 (e)
67.97 %
27.86 %
20.02 %
Jan 1, 2027 (e)
67.97 %
28.49 %
20.59 %
Jan 1, 2028 (e)
67.97 %
29.15 %
21.23 %

Coloplast A/S Stock Revenue, EBIT, Earnings per Share

The Coloplast A/S earnings per share therefore indicates how much revenue Coloplast A/S has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
91.12 DKK
29.81 DKK
22.63 DKK
Jan 1, 2022
106.10 DKK
32.47 DKK
22.11 DKK
Jan 1, 2023
113.69 DKK
31.76 DKK
22.19 DKK
Jan 1, 2024
120.19 DKK
32.40 DKK
22.46 DKK
Jan 1, 2025
123.66 DKK
34.03 DKK
16.13 DKK
Jan 1, 2026 (e)
130.32 DKK
36.30 DKK
26.09 DKK
Jan 1, 2027 (e)
139.61 DKK
39.77 DKK
28.74 DKK
Jan 1, 2028 (e)
148.69 DKK
43.35 DKK
31.56 DKK

Coloplast A/S business model & stock analysis

Coloplast A/S is a Danish company that has been manufacturing products for people with stoma, incontinence, and wound care needs since 1957. The company's headquarters is located in Humlebæk, Denmark, and it employs over 12,000 employees worldwide. Translated: Coloplast A/S is a Danish company that has been manufacturing products for people with stoma, incontinence, and wound care needs since 1957. The company's headquarters is located in Humlebæk, Denmark, and it employs over 12,000 employees worldwide.

Coloplast A/S SWOT Analysis

Strengths

Coloplast A/S has several strengths that contribute to its success in the market. These strengths include a strong brand reputation, a wide range of innovative products, and a global presence. The company has established itself as a market leader in the healthcare industry, known for its high-quality and reliable products.

Coloplast A/S has built a strong brand reputation over the years, earning the trust and loyalty of customers worldwide. The company is recognized for its commitment to customer satisfaction and delivering effective healthcare solutions.

Coloplast A/S consistently introduces innovative products that address the evolving needs of customers. Its extensive product portfolio includes advanced medical devices and supplies, offering various solutions for ostomy care, continence care, and wound care.

With a global presence in over 100 countries, Coloplast A/S enjoys a widespread distribution network. This extensive reach allows the company to serve a diverse customer base and penetrate different markets, contributing to its revenue growth and market share.

Weaknesses

Although Coloplast A/S is a robust company, it also faces certain weaknesses that need to be addressed to maintain its competitive edge in the market. These weaknesses include dependence on a limited number of suppliers, vulnerability to regulatory changes, and higher pricing compared to some competitors.

Coloplast A/S sources its raw materials and components from a limited number of suppliers, making it susceptible to disruptions in the supply chain. Any issues or delays in the supply chain could impact the company's manufacturing capabilities and product availability.

As a healthcare company, Coloplast A/S is subject to strict regulations governing the manufacturing, marketing, and sale of its products. Changes in regulatory requirements or non-compliance with existing regulations could pose challenges for the company and potentially impact its operations.

In comparison to some competitors, Coloplast A/S products are relatively higher priced. This pricing strategy may limit the company's market penetration and pose challenges in price-sensitive markets where competitors offer more affordable alternatives.

Opportunities

Coloplast A/S operates in a dynamic market that presents several opportunities for growth and expansion. These opportunities include emerging markets, increasing demand for advanced healthcare solutions, and technological advancements in the healthcare industry.

Expanding into emerging markets can provide Coloplast A/S with new customer segments and revenue streams. These markets often have a growing population, increasing healthcare awareness, and expanding healthcare infrastructure, creating a conducive environment for the company's products.

As the global population ages and healthcare needs continue to evolve, there is an increasing demand for advanced healthcare solutions. Coloplast A/S can capitalize on this trend by developing and offering innovative products that improve patient outcomes and quality of life.

Technological advancements in the healthcare industry provide Coloplast A/S with opportunities to create new and improved products. By investing in research and development, the company can leverage these advancements to enhance its product offerings and maintain a competitive edge.

Threats

Coloplast A/S faces various external threats that could impact its business operations and market position. These threats include intense competition, changing market dynamics, and economic uncertainties caused by factors such as currency fluctuations and geopolitical tensions.

The healthcare industry is highly competitive, with numerous companies vying for market share. Coloplast A/S faces competition from both established players and emerging companies, requiring it to continually innovate and differentiate its products to maintain its market position.

Market dynamics within the healthcare industry can rapidly change due to factors such as evolving customer preferences, shifting regulations, and advances in technology. Coloplast A/S must adapt to these changes and proactively anticipate market trends to remain competitive.

Economic uncertainties, including currency fluctuations and geopolitical tensions, can impact Coloplast A/S's business operations and financial performance. Changes in exchange rates and instability in global markets may affect the company's revenue, profitability, and supply chain.

Coloplast A/S Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Coloplast A/S historical P/E ratio, EBIT multiple, and P/S ratio

Coloplast A/S annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Coloplast A/S shares outstanding

The number of shares of Coloplast A/S was 225.4 M in 2025. This indicates how many shares Coloplast A/S is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
213.20 M Stocks
Jan 1, 2022
212.80 M Stocks
Jan 1, 2023
215.50 M Stocks
Jan 1, 2024
224.90 M Stocks
Jan 1, 2025
225.40 M Stocks
Jan 1, 2026 (e)
225.40 M Stocks
Jan 1, 2027 (e)
225.40 M Stocks
Jan 1, 2028 (e)
225.40 M Stocks

Coloplast A/S stock splits

In Coloplast A/S's history, there have been no stock splits.

Coloplast A/S Dividend History

36 years of dividend payments · 12 consecutive increases

YearAnnual DividendYoY ChangePayments
202523.00DKK↑ 1.3%2×
May 8, 20255.00DKK↑ 604.2%1/2
Dec 5, 202518.00DKK↑ 260.0%2/2
202422.71DKK↑ 8.1%3×
202321.00DKK↑ 5.0%2×
202220.00DKK↑ 5.3%2×
202119.00DKK↑ 5.6%2×
202018.00DKK↑ 5.9%2×
201917.00DKK↑ 6.3%2×
201816.00DKK↑ 6.7%2×
201715.00DKK↑ 11.1%2×
201613.50DKK↑ 8.0%2×

Coloplast A/S dividend history and estimates

In 2025, Coloplast A/S paid a dividend amounting to 23.00 DKK. Dividend means that Coloplast A/S distributes a portion of its profits to its owners.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details
Date
Dividend
Dividend (Estimate)
Jan 1, 2021
19.00 DKK
0.00 DKK
Jan 1, 2022
20.00 DKK
0.00 DKK
Jan 1, 2023
21.00 DKK
0.00 DKK
Jan 1, 2024
22.71 DKK
0.00 DKK
Jan 1, 2025
23.00 DKK
0.00 DKK
Jan 1, 2026 (e)
18.00 DKK
18.00 DKK
Jan 1, 2027 (e)
0.00 DKK
38.15 DKK
Jan 1, 2028 (e)
0.00 DKK
40.42 DKK

Coloplast A/S dividend payout ratio

In 2025, Coloplast A/S had a payout ratio of 142.58%. The payout ratio indicates the percentage of the company's profits that Coloplast A/S distributes as dividends.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Payout ratio
Details
Date
Payout ratio
Jan 1, 2021
83.95 %
Jan 1, 2022
90.44 %
Jan 1, 2023
94.62 %
Jan 1, 2024
164.73 %
Jan 1, 2025
142.58 %
Jan 1, 2026 (e)
137.98 %
Jan 1, 2027 (e)
132.71 %
Jan 1, 2028 (e)
128.08 %

Current Coloplast A/S forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
4.55 %
Buy
33.33 % (9)
Hold
59.26 % (16)
Sell
7.41 % (2)
12M Price Target
642.60
Last Price
429.40
Currency
DKK
12M Return Potential
49.65 %
LTM Return
0 %

Coloplast A/S Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
5/9/20246.30DKK-6.82 BDKK-2024 Q2
2/1/20246.22DKK-6.77 BDKK-2024 Q1
8/15/20237.17DKK-6.45 BDKK-2023 Q3
5/3/20237.17DKK-6.28 BDKK-2023 Q2
1/23/20236.36DKK-6.21 BDKK-2023 Q1
11/7/20226.13DKK-6.15 BDKK-2022 Q4
8/17/20225.92DKK-5.81 BDKK-2022 Q3
5/5/20225.77DKK-5.42 BDKK-2022 Q2
1/25/20225.73DKK-5.15 BDKK-2022 Q1
11/1/20216.13DKK-5.13 BDKK-2021 Q4
...

EESG©

Eulerpool ESG Scorecard© for the Coloplast A/S stock

72/100
78
Environment
81
Social
58
Governance
E

Environment

20
Scope 1 - Direct Emissions21,282
Scope 2 - Indirect emissions from purchased energy32,170
Scope 3 - Indirect emissions within the value chain197,836
Total CO₂ emissions53,452
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees62
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Coloplast A/S shareholder structure

% Name
2.57909%
Flossbach von Storch AG
Flossbach von Storch AG
1.85357%
The Vanguard Group, Inc.
The Vanguard Group, Inc.
1.18008%
Comgest S.A.
Comgest S.A.
1.02243%
BlackRock Institutional Trust Company, N.A.
BlackRock Institutional Trust Company, N.A.
0.88822%
Handelsbanken Kapitalförvaltning AB
Handelsbanken Kapitalförvaltning AB
0.67335%
Nordea Funds Oy
Nordea Funds Oy
...

Coloplast A/S Executives and Management Board

16 members · avg. age 60 · 38 % women

AL

Mr. Anders Lonning-Skovgaard (53)

Chief Financial Officer, Executive Vice President, Member of the Executive Leadership Team

11.30 M DKK

Management

AR

Mr. Allan Rasmussen (58)

Executive Vice President - Global Operations, Member of the Executive Leadership Team · since 2014

9.90 M DKK
LR

Mr. Lars Rasmussen (66)

Interim President, Interim Chief Executive Officer, Member of the Executive Leadership Team, Director

1.84 M DKK
DR

Ms. Dorthe Ronnau (59)

Executive Vice President - People and Culture, Member of the Executive Leadership Team

–
TJ

Mr. Thomas Johns

Executive Vice President - Interventional Urology, Member of the Executive Leadership Team

–
FS

Mr. Fertram Sigurjonsson

Executive Vice President - Wound & Tissue Repair, Member of the Executive Leadership Team

–
CR

Ms. Caroline Vagner Rosenstand

Executive Vice President - Chronic Care Commercial, Member of the Executive Leadership Team

–

Board of Directors

NL

Mr. Niels Louis-Hansen (77)

Deputy Chairman of the Board

938,000.00 DKK
MW

Ms. Marianne Wiinholt (59)

Independent Director

880,000.00 DKK
CH

Mr. Carsten Hellmann (60)

Independent Director

690,000.00 DKK
JN

Ms. Jette Nygaard-Andersen (57)

Interim Independent Chairman of the Board

600,000.00 DKK
AB

Ms. Annette Bruls (54)

Independent Director

600,000.00 DKK
TB

Mr. Thomas Barfod (54)

Director, Employee Representative

450,000.00 DKK

Frequently asked questions about Coloplast A/S

The business model of Coloplast A/S revolves around developing and manufacturing medical devices and services that cater to the needs of individuals with intimate healthcare needs. As a leading global supplier, Coloplast focuses on urology, ostomy, continence, wound care, and skin care products. By constantly innovating and collaborating with healthcare professionals, Coloplast aims to improve the quality of life for patients worldwide. With its customer-centric approach, the company provides advanced medical solutions, education, and support to help individuals regain their independence and confidence. Coloplast A/S is committed to delivering high-quality products and services that empower individuals to live an active and fulfilling life.

Coloplast A/S is primarily active in the healthcare industry.

The main competitors of Coloplast A/S in the market include Medtronic, Hollister Incorporated, and Convatec.

Coloplast A/S is a renowned Danish medical device company specializing in developing and manufacturing products for ostomy care, urology, continence care, and wound care. Founded in 1957, Coloplast has established itself as a global leader in its field, serving patients in more than 140 countries. With a strong focus on innovation, Coloplast continuously strives to improve the quality of life for individuals with intimate healthcare needs. The company's success is attributed to its commitment to customer-centricity and its ability to anticipate and adapt to changing market demands. Over the years, Coloplast has consistently delivered innovative solutions and has built a reputation for providing exceptional products and services in the healthcare industry.

Coloplast A/S, a leading medical device company, has achieved several significant milestones throughout its history. The company has a strong track record of innovation and has consistently introduced groundbreaking products to the market. Coloplast A/S introduced the world's first disposable ostomy appliance in 1954, revolutionizing care for ostomy patients. In recent years, the company has focused on expanding its product portfolio in urology and continence care, bringing advanced solutions to patients suffering from bladder and bowel dysfunctions. With a commitment to improving the quality of life for individuals with intimate healthcare needs, Coloplast A/S continues to make strides in the medical device industry.

Coloplast A/S is primarily present in a diverse range of countries and regions worldwide. The company has a strong global presence, serving markets in Europe, North America, Latin America, Asia-Pacific, the Middle East, and Africa. With a focus on providing innovative medical solutions, Coloplast A/S has established its footprint in numerous countries, including the United States, Germany, France, China, Japan, Brazil, Australia, and South Africa. Through its widespread reach, Coloplast A/S ensures that its advanced healthcare products and services are accessible to patients and healthcare professionals across different regions, contributing to improved quality of life and better healthcare outcomes.

Coloplast A/S represents values of compassion, innovation, and responsibility in its corporate philosophy. As a global healthcare company specializing in medical products and services, Coloplast A/S is dedicated to improving the lives of individuals with intimate healthcare needs. The company emphasizes care and understanding towards its customers, striving to develop innovative solutions that enhance their quality of life. Coloplast A/S's commitment to responsible business practices is reflected in its focus on sustainability, ethics, and transparency. With its strong emphasis on compassion, innovation, and responsibility, Coloplast A/S stands as a leading healthcare company, providing essential products and services to improve the well-being of individuals worldwide.

Analysts currently set an average price target of 658.22 DKK for the Coloplast A/S stock (median: 642.60 DKK), implying +53.3 % versus the latest price. The consensus is based on 27 analyst ratings.

Coloplast A/S Analyst Price Targets 2026

27 analysts currently rate the Coloplast A/S stock: 9 recommend buying, 16 holding and 2 selling. For 2026, analysts expect Coloplast A/S to generate revenue of 29.37 B DKK and earnings per share of 26.09 DKK.

Coloplast A/S Analyst Price Targets 2026

Converted at the current exchange rate, the Coloplast A/S share trades at 57.55 EUR (429.40 DKK).

The Coloplast A/S share (COLO B.CO) is listed on 10 stock exchanges, including: XETRA (CBHD.DE), Frankfurt (CBHD.F), München (CBHD.MU), Düsseldorf (CBHD.DU), London (0QBO.L), SIX (Zürich) (COLOB.SW), Wien (COLO.VI).

Coloplast A/S is a global company specializing in the development, manufacture, and distribution of medical devices and healthcare products. The company is divided into different business areas that focus on different customer needs. Its main business areas include continence care, wound care, and surgical products. Coloplast also offers products and services for animal continence care and wound care. The company is committed to providing high-quality products and improving patient care through innovation and collaboration with healthcare professionals. Coloplast operates in over 100 countries worldwide and strives to be a leading provider in the healthcare market.

The expected revenue of Coloplast A/S is 29.37 B DKK. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Coloplast A/S is 5.88 B DKK. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Coloplast A/S is currently 16.46. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Coloplast A/S stock.

The price-to-sales ratio (P/S) of Coloplast A/S is currently 3.30. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Coloplast A/S stock.

The Eulerpool Quality Score for Coloplast A/S is 7/10.

The ISIN of Coloplast A/S is DK0060448595. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Coloplast A/S is A1KAGC. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Coloplast A/S is COLO B.CO. The ticker symbol is used to trade Coloplast A/S shares on the stock exchange.

Over the past 12 months, Coloplast A/S paid a dividend of 23.00 DKK . This corresponds to a dividend yield of about 5.36 %. For the coming 12 months, Coloplast A/S is expected to pay a dividend of 38.15 DKK.

The current dividend yield of Coloplast A/S is 5.36 %.

Coloplast A/S pays a dividend, distributed in the months of , , , .

Coloplast A/S paid dividends every year for the past 36 years.

For the upcoming 12 months, dividends amounting to 38.15 DKK are expected. This corresponds to a dividend yield of 8.88 %.

Coloplast A/S is assigned to the 'Health' sector.

To receive the latest dividend of Coloplast A/S from amounting to 18 DKK, you needed to have the stock in your portfolio before the ex-date on .

The last dividend was paid out on .

In the year 2025, Coloplast A/S distributed 21 DKK as dividends.

The dividends of Coloplast A/S are distributed in DKK.

All fundamentals and in-depth analysis of Coloplast A/S

Our stock analysis for Coloplast A/S stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Coloplast A/S. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Coloplast A/S Stock
Coloplast A/S Revenue→
Coloplast A/S Stock
Coloplast A/S Net Income→
Coloplast A/S Stock
Coloplast A/S P/E→
Coloplast A/S Stock
Coloplast A/S P/S→
Coloplast A/S Stock
Coloplast A/S EBIT→
Coloplast A/S Stock
Coloplast A/S Dividend→
Coloplast A/S Stock
Coloplast A/S Directors Dealings→
Coloplast A/S Stock
Coloplast A/S Stocks→
Coloplast A/S Stock
Coloplast A/S Market capitalization→
Coloplast A/S Stock
Coloplast A/S Debt→
Coloplast A/S Stock
Coloplast A/S Liabilities→
Coloplast A/S Stock
Coloplast A/S Equity→
Coloplast A/S Stock
Coloplast A/S AAQS→
Coloplast A/S Stock
Coloplast A/S Employees→
Coloplast A/S Stock
Coloplast A/S ROE→
Coloplast A/S Stock
Coloplast A/S ROA→
Coloplast A/S Stock
Coloplast A/S ROCE→
Coloplast A/S Stock
Coloplast A/S News→
Coloplast A/S Stock
Coloplast A/S Analyst Price Targets→

Health Stocks

Coltene HoldingCollplant BiotechnologiesComera Life Sciences HoldingsCollegium PharmaceuticalCommunity Health SystemsColinz LaboratoriesCompass PathwaysColan Totte CoCompass TherapeuticsCoherus OncologyCompuMedCohance LifesciencesAll Stocks A–Z →